Role of thrombotic and fibrinolytic alterations in the pathogenesis and treatment of osteonecrosis

Journal of Rheumatology

Volumn 34, Issue 3, 2007, Pages 466-468

  Mont, Michael A ^a   Ulrich, Slif D ^a   Seyler, Thorsten M ^a  

^a SINAI HOSPITAL OF BALTIMORE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; ANTILIPEMIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; CARDIOLIPIN ANTIBODY; CORTICOSTEROID; IMMUNOGLOBULIN G ANTIBODY; LIPOPROTEIN A; PLASMINOGEN ACTIVATOR INHIBITOR; VASODILATOR AGENT;

BONE NECROSIS; CORTICOSTEROID THERAPY; EDITORIAL; FIBRINOLYSIS; HIGH RISK PATIENT; HUMAN; PATHOGENESIS; PERTHES DISEASE; PHENOTYPE; PRIORITY JOURNAL; THROMBOSIS;

APOPROTEIN(A); FIBRINOLYSIS; HUMANS; OSTEONECROSIS; RISK FACTORS; THROMBOPHILIA;

EID: 33847626359     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Editorial

References (17)

1. Mont MA, Jones LC, Hungerford DS. Nontraumatic osteonecrosis of the femoral head: ten years later. J Bone Joint Surg Am 2006;88:1117-32.
2. Mont MA, Hungerford DS. Non-traumatic avascular necrosis of the femoral head. J Bone Joint Surg Am 1995;77:459-74.
3. Inoue S, Hori M, Asano T, et al. Risk factors for nontraumatic osteonecrosis of the femoral head after renal transplantation. J Orthop Sci 2003;8:751-6.
4. Chernetsky SG, Mont MA, LaPorte DM, Jones LC, Hungerford DS, McCarthy EF. Pathologic features in steroid and nonsteroid associated osteonecrosis. Clin Orthop Relat Res 1999;368:149-61.
5. Griffith JF, Antonio GE, Kumta SM, et al. Osteonecrosis of hip and knee in patients with severe acute respiratory syndrome treated with steroids. Radiology 2005;235:168-75.
6. Cui Q, Wang GJ, Su CC, Balian G. The Otto Aufranc Award. Lovastatin prevents steroid induced adipogenesis and osteonecrosis. Clin Orthop Relat Res 1997;344:8-19.
7. Glueck CJ, Freiberg RA, Sieve L, Wang P. Enoxaparin prevents progression of stages I and II osteonecrosis of the hip. Clin Orthop Relat Res 2005;435:164-70.
8. Glueck CJ, Freiberg R, Glueck HI, Tracy T, Stroop D, Wang Y. Idiopathic osteonecrosis, hypofibrinolysis, high plasminogen activator inhibitor, high lipoprotein(a), and therapy with Stanozolol. Am J Hematol 1995;48:213-20.
9. Agarwala S, Jain D, Joshi VR, Sule A. Efficacy of alendronate, a bisphosphonate, in the treatment of AVN of the hip. A prospective open-label study. Rheumatology Oxford 2005;44:352-9.
10. Fortmann SP, Marcovina SM. Lipoprotein(a), a clinically elusive lipoprotein particle. Circulation 1997;95:295-6.
11. Glueck CJ, Freiberg I, Glueck HI, et al. Hypofibrinolysis: a common major cause of osteonecrosis. Am J Hematol 1964; 45:156-66.
12. Posan E, Szepesi K, Gaspar L, et al. Thrombotic and fibrinolytic alterations in the aseptic necrosis of femoral head. Blood Coagul Fibrinolysis 2003;14:243-8.
13. Berger CE, Kroner A, Stiegler H, Erdel M, Haas OA, Engel A. Hypofibrinolysis, lipoprotein(a), and plasminogen activator inhibitor. Clin Orthop Relat Res 2002;397:342-9.
14. Lee JS, Koo KH, Ha YC, et al. Role of thrombotic and fibrinolytic disorders in osteonecrosis of the femoral head. Clin Orthop Relat Res 2003;270-6.
15. Jones LC, Mont MA, Le TB. Procoagulants and osteonecrosis. J Rheumatol 2003;30:783-91.
16. Mont MA, Glueck CJ, Pacheco IH, Wang P, Hungerford DS, Petri M. Risk factors for osteonecrosis in systemic lupus erythematosus. J Rheumatol 1997;24:654-62.
17. Hirata T, Fujioka M, Takahashi K, et al. Low molecular weight phenotype of apolipoprotein(a) is a risk factor of corticosteroid-induced osteonecrosis of the femoral head after renal transplant. J Rheumatol 2007;34:516-22.